ESR1 and breast cancer: The in vitro cytotoxicity assays demonstrated that expanded antigen-specific CTLs could effectively lyse peptide-pulsed targets and breast cancer cells expressing five peptides as the most immunogenic candidates, derived from D538G, Y537S, and E380Q, which are the three most prevalent ESR1 mutations [185].